Repare Therapeutics Inc.

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Repare Therapeutics Inc. trades as RPTX on NASDAQ. The company is classified in Healthcare / Biotechnology and reports in USD.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $53.48M of revenue and -$84.69M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Repare Therapeutics Inc. can be compared against peers such as Acrivon Therapeutics, Inc. Common Stock, ALX Oncology Holdings Inc., aTyr Pharma, Inc., Biomea Fusion, Inc., CAMP4 Therapeutics Corporation, Precision BioSciences, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $114.24M, beta of 0.96, and return on equity of -56.0%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

RPTX currently shows total debt of $1.93M and beta of 0.96. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: SC 13G/A (2026-05-14 00:00:00), 15-12G (2026-02-19 00:00:00), EFFECT (2026-01-30 00:00:00), 4 (2026-01-30 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.reparerx.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.